Introduction
Ageing is associated with alterations in cardiovascular structure and function that are partly driven by chronic inflammation and oxidative stress. 1 At a cellular level, ageing is characterized by a process known as cellular senescence, a state of irreversible growth arrest.
Normally, cellular senescence is a protective process, keeping the body safe from tumour growth by inhibiting uncontrolled proliferation. At the same time, it is deemed responsible for ageing-associated changes in several organs including the cardiovascular system. 2, 3 Although senescent cells undergo a permanent growth arrest, they remain viable and actively secrete inflammatory mediators until removed by the immune system. As such, these cells can negatively influence the neighbouring microenvironment by a phenomenon known as the senescenceassociated secretory phenotype (SASP). 4 ,5 Cellular senescence and SASP play an important role in cardiovascular ageing and disease. [6] [7] [8] Cells can enter the senescent state by DNA damage caused by intrinsic and extrinsic stress factors, known as 'stress-induced premature senescence' (SIPS). 9 Oxidative stress and hyperglycaemia are two major factors causing SIPS. 10, 11 Stress-induced DNA-damage provokes a DNA-damage response, which subsequently leads to activation of two important cell cycle regulatory pathways, p53 and p16. [12] [13] [14] The exact nature of activation of either of these two pathways in the context of cellular senescence depends on species and cell type. [15] [16] [17] [18] The p53 protein contains several functional domains that can be post-translationally modified (via phosphorylation and acetylation), resulting in different cellular responses such as apoptosis, senescence, and tumour suppressor activity. 19 Acetylation of p53 on six C-terminal lysine (k) residues (k317, k370, k372, k373, k381, k382, and k386) in response to oxidative stress leads to its activation. 14, 17, 20 Subsequently, p21 is activated, leading to cell cycle arrest. 15 Therefore, activation of both the p53 or p16 pathway is frequently used together with senescence-associated-b-galactosidase (SA-b-gal) staining to confirm cellular senescence. [21] [22] [23] [24] [25] [26] [27] Neuregulins (NRGs) belong to the epidermal growth factor family and are known to induce growth and differentiation of several cell types. NRG-1 is produced by cardiac and vascular endothelial cells (ECs) and acts through ErbB2, ErbB3, and ErbB4 tyrosine kinase receptors expressed on ECs and smooth muscle cells (SMCs) in a paracrine and autocrine fashion. [28] [29] [30] In the past two decades, the cardioprotective effects of NRG-1 have been extensively studied. [31] [32] [33] [34] [35] [36] NRG-1 has been shown to attenuate development of cardiac dysfunction in several animal models of heart failure and recombinant human NRG-1 (rhNRG-1) is currently tested in clinical trials as a novel treatment for heart failure. 37 In addition, NRG-1 is known to influence apoptosis and cell death pathways. 29, 38 However, the effects of NRG-1 on cellular senescence in cardiovascular diseases are not known. Therefore, we studied the effects of NRG-1 on stressinduced cardiovascular senescence, both in vitro and in vivo in a mouse model of Type 1 diabetes. To study vascular senescence in diabetic mice, a model of Type 1 diabetes induced by administration of streptozotocin (STZ) was selected. In comparison to models of Type 2 diabetes, this model leads to cellular senescence in the vasculature within a relatively short period of time.
Methods

Cell culture
Rat aortic ECs and SMCs were isolated from male Sprague Dawley rats. Freshly isolated aortas were incubated in 1 mg/mL collagenase Type II collagenase (CLS), 1 mg/mL soybean trypsin inhibitor and 0.74 ml/mL elastase (all from Worthington, US) for 15 min at 37 C to remove the adventitia. Thereafter, the aorta was cut longitudinally and placed in a fresh enzyme solution for 20 min at 37 C to isolate ECs, then the remaining aortic tissue was incubated in fresh enzyme solution for 1 h at 37 C to obtain SMCs. ECs were cultured in Dulbecco's Modified Eagle Medium (DMEM), supplemented with 10% fetal bovine serum (FBS, Sigma, Belgium). SMCs were grown in DMEM/Nutrient Mixture F-12 (DMEM-F12), supplemented with 10% FBS. All media contained 100 U/mL penicillin and 100 mg/mL streptomycin (Gibco, USA). Experiments were conducted on cells from passage Number 3 to 7. Cultures with > _95% purity were used for each cell type. For SMCs, alpha smooth muscle actin antibody (Sigma A2547, 1:1000) staining was used to measure the purity of cell cultures. The purity of ECs was measured using CD31 (BD PharmingenTM 557355 for mouse and BD PharmingenTM 550300 for rat, 1:1000) labelled with Alexa Flour 488 (Molecular Probes by Life Technologies) and visualized using an automated cell counter (Countess II FL, ThermoFisher Scientific, USA).
To induce cellular senescence, 1 Â 10 4 cells per well (24-well plate) were treated with hydrogen peroxide (30 lM, H 2 O 2 , Fisher BioReagents) for 2 h. It is well-established that short exposure to H 2 O 2 leads to senescence whereas longer exposure leads to apoptosis. 10 To render cells quiescent, medium was switched to low FBS (1%) conditions 24 h before the experiments. After exposure to H 2 O 2 , medium was replaced with 10% FBS supplemented medium for the remainder of the study. One-half of the wells were pre-treated with rhNRG-1 (20 ng/mL, Peprotech) 30 min before exposure to stress stimulus and during the entire experiment. We isolated 13 batches of SMCs from 13 animals and 7 batches of ECs from 7 animals. For each experiment, 4-6 batches of cells were used in almost the same cell serial passaging (3-7). Within each batch of cells, treatments were done in four fold simultaneously and an average was used in the statistical analysis. In total, 1 Â 10 4 cells/well were plated initially and 100 total cells per well were randomly counted towards of SA-b-gal positive cells, using Image J software in a blinded manner. In total, > _95% of cells used for this experiment was viable. Cell viability was monitored using propidium iodide (PI). A comparable well of cells was subjected to PI to label death cells. Briefly, cells were labelled with 1 mg/mL PI (Molecular Probes) and 5 mg/mL Hoechst (Life Technologies) and immediately visualized using fluorescent microscopy (EVOS FL Cell Imaging System, ThermoFischer Scientific). 
Animal models
SM22a-Creþ (n = 20 survival) served as wild-type control. C57BL/6 mice (n = 27 survival) were obtained from Charles River. Diabetes mellitus Type 1 was induced in all described mouse strains at the age of 13 weeks by low-dose STZ treatment (60 mg/kg in 0.05 M sodium citrate, 5 consecutive days, intraperitoneal). Age-matched control mice were sham-treated with citrate buffer. Blood glucose levels were determined (glucometer Elite XL) and mice with blood glucose levels below 300 mg/dL 2 weeks after the STZ injections were excluded from the experiment. Mice were randomized to receive either daily rhNRG-1 injections (20 mg/kg, intraperitoneal) or vehicle for 9 weeks. At the end of follow-up, mice and rats used to isolate aortic ECs and SMCs were euthanized with an overdose of pentobarbital (100 mg/kg intraperitoneal, CEVA Santé Animale). Tissues, including aorta and heart were embedded in Neg-50 frozen section medium (ThermoFisher).
Male Sprague Dawley rats used to isolate aortic ECs and SMCs were euthanized with an overdose intraperitoneal injection of 100 mg/kg pentobarbital.
SA-b-gal staining
Senescence was determined by using the Senescence Cells Histochemical Staining Kit (Sigma CS0030) following manufacturer's instructions. Briefly, 1 Â 10 4 cells were incubated with fixation buffer for 10 min at room temperature. After washing steps, cells were incubated with staining mixture (containing X-gal) at 37 C for 24-30 h and then counterstained with Nuclear Fast Red. Light microscopic pictures were acquired with Universal Grab 6.1 software using an Olympus BX40 microscope. The percentage of SA-b-gal positive cells was quantified using Image J software in a blinded manner. The same staining kit was used for isolated aortic tissue of the in vivo experiments. Frozen sections (5 mm) were incubated for 48 h at 37 C without CO 2 , followed by counterstaining with Nuclear Fast Red. Total area of positive staining was calculated using Image J software and normalized to total surface area of each aorta.
Histology
Fluorescent staining was performed on frozen sections of the aorta with specific antibodies against acetyl-p53 (rabbit anti-acetyl-p53 (lys 317), Sigma SAB4503014) as a senescence marker and against CD31 (rat anti-CD31, BD Pharmingen 550274) as a marker for ECs. Furthermore, ErbB4 and ErbB3 receptors were stained with specific antibodies against ErbB4 [rabbit anti-ErbB4 antibody (C-18), Santa Cruz, USA, sc-283] and ErbB3 (rabbit anti-HER3/ErbB3, Cell Signaling Technology, The Netherlands, D22C5). Nuclei were counterstained using 4 0 ,6-diamidino-2-phenylindole dihydrochloride (DAPI, Sigma). Images were taken using the EVOS FL Cell Imaging System (ThermoFischer Scientific). Total number of cells and number of ac-p53 positive cells were calculated to make a percentage of positive cells in ECs and SMCs.
Western blotting
Cultured cells were harvested in Radioimmunoprecipitation assay (RIPA) lysis buffer (Sigma) supplemented with protease and phosphatase inhibitors (complete Mini and PhosSTOP, Roche) on ice for 5 min. Aorta segments were mixed in RIPA lysis buffer using a Precellys 24 tissue homogenizer (Bertin Instruments). After centrifugation to pellet non-dissolved material, protein concentration of the supernatant of each sample was determined using the bicinchoninic acid method (BCA, ThermoFischer). Equal amounts of protein were separated on Bolt 4-12% bis-tris gels (Invitrogen) and blotted onto polyvinylidene fluoride membranes. Membranes were blocked in Odyssey Blocking Buffer (Li-Cor Biosciences) and probed with primary antibody (overnight, 4 C). Following primary antibodies were used rabbit anti-acetylp53 antibody (Lys317, Sigma SAB4503014, 55 kDa), rabbit anti-p21 antibody 
Cell cycle analysis
Cell cycle analysis was performed using the Vindelov method. 39 Briefly, cells were permeabilized with trypsin, followed by ribonuclease treatment to ensure DNA staining only. Finally, nuclei were stained with PI (Molecular Probes) and analysed by flow cytometry (BD FACScan) to quantify DNA content. Results were analysed with FCS Express 4 Flow software (De Novo software).
Statistical analysis
All data were analysed using Graph-pad Prism software version 6.0 and presented as Mean ± SD. When two groups were compared, an unpaired twotailed t-test was used. When four groups were compared, two-way Analysis of variance (ANOVA) was used with genotype and cell passage number as factors. When three groups were compared, group data were checked for equality of variances (Brown-Forsythe test) and analysed with one-way ANOVA followed by Bonferroni correction for multiple comparisons. When variances were significantly different, Kruskal-Wallis test was used instead. Results were considered significant at P < 0.05.
Results
NRG-1 attenuated stress-induced cellular senescence in vitro
We determined the effects of NRG-1 on senescence induced by oxidative stress in cultured vascular SMCs and ECs ( Figure 1A) . In both cell types, rhNRG-1 significantly decreased the number of SA-b-gal positive cells induced by H 2 O 2 ( Figure 1B and C) . Moreover, NRG-1 also attenuated the increase in cell surface area-another marker of senescencein the same cells ( Figure 1D and E) . Figure 1J and K shows representative western blot analyses of the expression of cell cycle regulators acetyl-p53 and p21 in both cultured cell types. Densitometric analysis confirmed significant higher expression of both acetyl-p53 and p21 in H 2 O 2 -treated conditions. This was attenuated by treatment with rhNRG-1 in all conditions, with the exception of p21 in SMCs ( Figure 1F-I ).
NRG-1 attenuated vascular senescence in a mouse model of Type 1 diabetes
The role of NRG-1 in cellular senescence was further explored in vivo using a mouse model of STZ-induced Type 1 diabetes. Diabetic C57BL/6 mice (STZ) showed extensive SA-b-gal positive staining compared with vehicle, which was attenuated when diabetic animals were treated with rhNRG-1 (Figure 2A and B) .
To define the cell type(s) evoking this cellular senescence signal, immunofluorescence staining was performed ( Figure 2C ). Significantly higher expression of acetyl-p53 was observed in both ECs and SMCs of STZ animals compared with vehicles, an increase that was prevented by rhNRG-1 treatment ( Figure 2D and E) .
Next, we confirmed these immunohistochemistry results with western blotting of aortic tissues using antibodies against acetyl-p53 and p21. Similar to the immunostaining, NRG-1 prevented the upregulation of acetyl-p53 and p21 protein levels in aortic tissue of diabetic animals ( Figure 2F and G) . Together, these data indicate that treatment with rhNRG-1 prevents cellular senescence in aortic ECs and SMCs of diabetic mice. Figure 2H shows western blot analysis of expression and phosphorylation of Akt, an important downstream pathway of the ErbB receptors. 40, 41 There was significantly higher phosphorylation of Akt in STZ-mice treated with rhNRG-1 ( Figure 2H ).
NRG-1 activates Akt signalling pathway
NRG-1 has no impact on the diabetic phenotype
Four weeks after STZ treatment, blood glucose levels amounted to 524 ± 63 mg/dL in STZ-treated C57BL/6 animals and 164 ± 29 mg/dL in the non-diabetic vehicle group. rhNRG-1 treatment did not reduce the blood glucose concentration (481 ± 46 mg/dL) in this experimental setting. Diabetic C57BL/6 mice showed a reduced body weight at the end of the study (22.42 ± 1.90 g) compared with the non-diabetic animals (28.45 ± 1.90 g). rhNRG-1 treatment did not further reduce the body weight (22.27 ± 1.80 g).
ErbB4 deficient SMCs show earlier signs of senescence in vitro
NRG-1 is a ligand to both ErbB3 and ErbB4 receptors. To locate these in the aorta, we performed immunofluorescence staining ( Figure 3A) . ErbB4 staining was most pronounced in SMCs whereas ErbB3 staining was most pronounced in ECs ( Figure 3A) . Because the most prominent NRG-1 receptor in the aorta appeared to be ErbB4 in SMCs, we developed a SMC-specific ErbB4 KO mouse. Mice with a floxed ErbB4 NRG-1 attenuates vascular senescence . Western blot analysis of (F) acetyl-p53 and (G) p21 (H) Akt and phosphorylated Akt (P-Akt) in aortic tissues. Mean ± SD. Data of D and E were analysed with one-way ANOVA followed by Bonferroni post hoc test. All other data were analysed using nonparametric Kruskal-Wallis test. *P < 0.05; **P < 0.01; ***P < 0.001. Ac-p53, acetyl-p53 protein; p21, cyclin-dependent kinase inhibitor 1, p21 protein; SMCs, smooth muscle cells; ECs, endothelial cells; STZ, streptozotocin; rhNRG-1, recombinant human neuregulin-1; SA-b-gal, senescence-associated-beta galactosidases. Figure 3B) . Immunofluorescence staining also confirmed that ErbB4 expression is significantly reduced in ErbB4
NRG-1 attenuates vascular senescence
SM22a-Creþ mice ( Figure 3C and D) . 
ErbB4 deficiency in SMCs accelerates vascular senescence in the diabetic mice
Using STZ, we induced diabetes in ErbB4 f/þ SM22a-Creþ mice and ErbB4 þ/þ SM22a-Creþ control littermates. Diabetic ErbB4 f/þ SM22a-Creþ mice showed significantly higher cellular senescence in the aorta in comparison to their diabetic wild-type littermates ( Figure 4A and B) .
Immunofluorescence staining of acetyl-p53 ( Figure 4C ) not only showed significantly more cellular senescence in diabetic ErbB4 f/þ SM22a-Creþ mice in comparison with their normal diabetic littermates but even a significant increase in cellular senescence in non-diabetic ErbB4 f/þ SM22a-Creþ in comparison with their normal non-diabetic littermates ( Figure 4D ). In addition, mortality was higher in diabetic ErbB f/þ SM22a-Creþ mice compared with diabetic ErbB þ/þ SM22a-Creþ mice ( Figure 4E) . Also, more cardiac hypertrophy was observed in the diabetic ErbB f/þ SM22a-Creþ mice compared with diabetic wild-type mice (Supplementary material online, Figure S1 ).
To rule out other mechanisms of cell death, markers of autophagy and apoptosis in vitro and in vivo were measured (Supplementary material online, Figure S2 ). Neither autophagy nor apoptosis was induced in these experiments.
ErbB4 deficiency in SMCs has no impact on diabetic phenotype
Blood glucose levels in Type 1 diabetic (STZ) ErbB4 f/þ SM22a-Creþ mice were 529 ± 47 mg/dL and 499 ± 38 mg/dL in their diabetic wild-type littermates. Baseline blood glucose levels in non-diabetic (vehicle) mice showed no differences between transgenic and wild-type mice (175 ± 5 mg/dL in ErbB4f/þ SM22a-Creþ mice vs. 172 ± 5 mg/dL in wild-type animals) (Supplementary material online, Figure S5) . Also, diabetes did not change ErbB3 and ErbB4 expression in ECs and SMCs in ErbB4 f/þ SM22a-Creþ mice and their wild-type littermates (ErbB4
SM22a-Creþ) (Supplementary material online, Figure S3 ). However, capillary density was increased in hearts of diabetic mice (Supplementary material online, Figure S4 ) and this increase was attenuated in hearts of ErbB4 deficient mice.
Discussion
This study provides evidence for the protective role of NRG-1 in vascular senescence. We demonstrated that rhNRG-1 inhibits oxidative stressinduced cellular senescence in cultured aortic ECs and SMCs. Moreover, aortic SMCs isolated from mice with a SMC-specific deficiency in the NRG-1 receptor ErbB4 (ErbB4 f/þ SM22a-Creþ) become prematurely senescent as compared with SMCs from wild-type littermates. In vivo, daily treatment of Type 1 diabetic mice with rhNRG-1 for 9 weeks attenuates diabetes-induced vascular senescence. Consistently, diabetes induces significantly more vascular senescence in mice deficient for the ErbB4 receptor in SMCs compared with their wild-type littermates.
The NRG-1/ErbB signalling system is important in cardiac development and pathophysiology. 36, 42 NRG-1 attenuates development of heart failure in several animal models, including diabetic cardiomyopathy. 37, [43] [44] [45] [46] rhNRG-1 is currently being tested in clinical trials as a novel treatment for heart failure. 47, 48 NRG-1 is produced by ECs and exerts its effects through ErbB tyrosin kinase receptors. 49 Although NRG-1 is most abundant in ECs, its ErbB receptors are widely expressed throughout the body, ranging from gastrointestinal, neuronal, respiratory, and cardiovascular system. [50] [51] [52] [53] In the vasculature, ErbB receptors are located on ECs as well as on the underlying SMCs. Therefore, endothelium-derived NRG-1 can play its role via a paracrine or autocrine signalling in both cell types. The NRG-1/ ErbB signalling system is crucial for vascular responses to stress. 49 ECs produce NRG-1 in response to inflammation, hypoxia, and oxidative stress. [54] [55] [56] In addition, there are data indicating that NRG-1 has antioxidant effects, 38, 57, 58 which could partly explain the protective effects against hydrogen peroxide in our cell culture experiments. NRG-1 is also a proangiogenic factor: it plays an important role in angiogenesis and arteriogenesis after ischaemic injury. 59 NRG-1 regulates endothelial progenitor cell biology by affecting their survival and differentiation capacity. 59, 60 Xu et al. 61 also demonstrated an anti-atherosclerotic effect of NRG-1 in ApoE-/-mice and showed NRG-1 prevents foam cell formation in primary cultured human monocyte-derived macrophages. Furthermore, NRG-1 reduces neointimal formation after vascular injury in rat, through a decreased vascular SMC proliferation and migration. 62 We add to this evidence demonstrating NRG-1 attenuates EC and SMC senescence, importantly influencing mortality. Two other important cell death mechanisms, autophagy and apoptosis, were not observed during this study in the aorta of diabetic animals in vivo, neither in vitro experiments.
Effects of NRG-1 on cellular proliferation and apoptosis have been well-described and are mainly ascribed to the activation of Akt and mitogen-activated protein kinases signalling proteins. 29, 38 However, no information is available on a potential role in cellular senescence. Interestingly, recent evidence suggests an effect of NRG-1 on ageing. 63 It has been shown that NRG-1 levels and its receptor ErbB4 are sustained throughout the entire life of the long-life naked mole rat, which NRG-1 attenuates vascular senescence could be the reason of its continued normal brain function and its concomitant normal activity. 63 Our data add to this evidence by showing that NRG-1 prevents premature senescence, an important ageing mechanism, both in vivo and in vitro. However, we were not able to detect significant levels of NRG-1 expression in aortic segments (data not shown), which might indicate that local paracrine signalling might be less important that signalling by circulating NRG-1. The effect of NRG-1/ErbB4 signalling on replicative senescence remains to be elucidated. In our NRG-1 receptor knockdown model, we chose to knockdown the ErbB4 receptor. NRG-1 exerts its effect via three different ErbB tyrosine kinase receptors: ErbB2, ErBb3, and ErbB4. Among these, ErbB4 is the only receptor with both ligand-binding domain and tyrosine kinase activity. 64, 65 The ErbB2 receptor lacks a ligand-binding domain, while ErbB3 lacks tyrosine kinase activity. Therefore, ErbB2 and ErbB3 need heterodimerization with other ErbB receptors to exert their effect. In addition, on immunofluorescence staining ErbB4 expression in aorta was more pronounced than ErbB3 expression. Although we did not observe any evidence of tumour formation in this study, one of the earliest findings regarding the important role of NRG-1/ErbB signalling system in the adult human heart, was made in cancer patients treated with an anti-ErbB2 drug (trastuzamab). 66 This finding supports the notion that ErbB2 might have a role in both tumorigenesis and cardioprotection.
The exact role of NRG-1 in balancing protective effects and tumour growth enhancing effects have still to be sorted out but recent evidence indicates that activation of ErbB4 by NRG-1 has cardioprotective effects while activation of ErbB3 by NRG-1 has growth enhancing effects. 67 Recent evidence supports the idea that cellular senescence plays a role in different cardiovascular diseases, including atherosclerosis, hypertension, and heart failure. 8, [68] [69] [70] [71] Atherosclerosis as a dominant contributor to cardiovascular diseases can be caused by senescence of ECs, vascular SMCs, and their progenitor cells. 69, [72] [73] [74] Human coronary ECs found on the surface of atherosclerotic plaques and vascular SMCs isolated from atherosclerotic vessels and advanced atherosclerotic plaques display features associated with cellular senescence, such as morphological features of premature senescence, increased SA-b-gal activity, upregulation of cell cycle regulators (p16, p21), decreased telomerase activity, and telomere shortening. 7, [75] [76] [77] As such, attenuation of vascular senescence by NRG-1 might be an important new therapeutic strategy to prevent cardiovascular disease. Here, we studied vascular senescence in larger arteries but not in resistance sized vessels. Therefore, although our findings are relevant for pathophysiological processes such as atherosclerosis, it is unclear if they are also relevant for physiological processes such as blood pressure regulation. In this study, we did not perform an in-depth investigation on the effect of NRG-1 on cardiac function but consistent with the literature diabetes led to an increased cardiac hypertrophy as well as increased capillary density. [78] [79] [80] The mechanisms by which partial ErbB4 deletion in SMCs could lead to decreased capillary density in the heart is unclear and remains to be elucidated.
Although the animal models used in this article do not show features of atherosclerosis, this study shows that NRG-1 prevents senescence in vascular ECs and SMCs in vitro and also in the vasculature of diabetic animals. Diabetes is the most common age-associated chronic disease with high morbidity and mortality. Approximately one-half of diabetic patients die due to cardiovascular diseases. 81 The NRG-1/ErbB signalling pathway has been reported to reverse cardiac remodelling observed in diabetic rats. 37, [43] [44] [45] Hyperglycaemia in Type 2 diabetes leads to p53 activation and myocyte cell death. 82 Another study shows the effect of advanced glycation end-products on the onset of premature epithelial cell senescence in diabetic nephropathy. 83 However, we did not observe significant amounts of cellular senescence in 28 weeks old db/db mice (BKS.Cg-þLepr db /þLepr db /OlaHsd), a mouse model of Type 2 diabetes (data not shown). In our experimental setting, the induction of diabetes mellitus by STZ is used as a source of endogenous oxidative stress that can induce senescence. The role of oxidative stress in the pathogenesis of vascular abnormalities in diabetes is well-established and oxidative stress is known to induce premature senescence through DNA damage. [84] [85] [86] In this study, we did not use the same stimulus for induction of senescence in the in vitro and in vivo experiments. For the in vivo experiments, STZ-injection caused a diabetes model with extremely high circulation glucose levels, independent of insulin secretion. 87 10, [88] [89] [90] In this study, a low dose (30 mm) is used to avoid other forms of cell death such as apoptosis and necrosis.
Indeed our results show premature senescence in STZ-treated mice regardless of genotype. Moreover, partial deletion of the ErbB4 receptor in SMCs led to an increased senescence and mortality in a model of Type 1 diabetes. Therefore, by deduction, we propose that inhibition of senescence provides a new window of opportunity to prevent atherosclerosis and its pathophysiology.
Conclusion
This study is the first to provide insight into the role of the NRG-1/ ErbB pathway in cellular senescence. Activation of NRG-1/ErbB signalling attenuates stress-induced cellular senescence in vitro and in vivo, whereas inhibition of this pathway causes the opposite. As such our data provide a novel mechanism by which NRG-1 exerts its protective effects. In addition, abating the process of cellular senescence may be an important therapeutic strategy to tackle age-related cardiovascular diseases.
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